RT Journal Article
SR Electronic
T1 Downregulation of <sup>18</sup>F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1815
OP 1819
DO 10.2967/jnumed.109.065367
VO 50
IS 11
A1 Lucia Nogová
A1 Ronald Boellaard
A1 Carsten Kobe
A1 Nikie Hoetjes
A1 Thomas Zander
A1 Stefan Hubert Gross
A1 Sasa Dimitrijevic
A1 Theodore Pellas
A1 Wolfgang Eschner
A1 Katja Schmidt
A1 Christopher Bangard
A1 Wendy Hayes
A1 Roman K. Thomas
A1 Markus Dietlein
A1 Giuseppe Giaccone
A1 Otto S. Hoekstra
A1 Adriaan A. Lammertsma
A1 Jürgen Wolf
YR 2009
UL http://jnm.snmjournals.org/content/50/11/1815.abstract
AB Everolimus downregulates glucose metabolism–associated genes in preclinical models. Inhibition of glucose metabolism measured by 18F-FDG PET was postulated to serve as a pharmacodynamic marker in everolimus-treated non–small cell lung cancer (NSCLC) patients. Methods: In 8 NSCLC patients treated with everolimus, the percentage change in 18F-FDG PET uptake (days 8 and 28 relative to baseline) was determined using a variety of summed standardized uptake value (SUV) measures. Both maximum and mean SUVs were used, with normalizations to body surface area and body weight and with and without correcting for plasma glucose levels. Results: In 5 patients, a reduction of 18F-FDG PET uptake on day 8 was observed with all methods, ranging from −12.8% to −72.2%. Conclusion: These observations demonstrate that inhibition of glucose metabolism is an early effect of everolimus treatment in NSCLC patients and can be assessed using 18F-FDG PET.